Advertisement

Assessment of Response to Treatment

  • R. E. Coleman
Chapter

Abstract

There are many treatments available for bone metastases and radiotherapy, endocrine manipulation and chemotherapy may all produce significant clinical improvement. Control of the tumour by systemic therapy reduces osteoclast activity allowing bone healing, mediated by osteoblasts, to occur. However, as assessment of response for most tumours is based on changes seen on serial plain radiographs, the precise effect of therapy is difficult to measure objectively. In 1977, on behalf of the Union Internationale Contre le Cancer (UICC), Hayward et al. defined criteria for objective assessment of response in advanced breast cancer (Table 6.1). These criteria have since been applied to assessment of response in other tumour types and although they are internationally accepted and have standardised the reporting of clinical trials, response in bone remains an imprecise entity.

Keywords

Bone Metastasis Advanced Breast Cancer Calcium Excretion Urinary Calcium Excretion Prostatic Acid Phosphatase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aabo K (1987) Prostate cancer: evaluation of response to treatment, response criteria, and the need for standardization of the reporting of results. Eur J Cancer Clin Oncol 23:231–237PubMedCrossRefGoogle Scholar
  2. Alexanian R, Gehan E, Bonnet J et al. (1973) Combination chemotherapy for multiple myeloma. Semin Haematol 10:135–147Google Scholar
  3. Bataille R, Delmas P, Sany J (1987) Serum bone gla-protein in multiple myeloma. Cancer 59:329–334PubMedCrossRefGoogle Scholar
  4. Bellamy EA, Nicholas D, Ward M, Coombes RC, Powles TJ (1987) Comparison of computed tomography and conventional radiology in the assessment of treatment response of lytic bony metastases in patients with carcinoma of the breast. Clin Radiol 38:351–355PubMedCrossRefGoogle Scholar
  5. Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC, Meunier PJ (1984) Serum bone GLA protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet i: 1091–1093Google Scholar
  6. Buamah PK, Johnson P, Skillen AW (1988) Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease. Br J Urol 62:581–583PubMedCrossRefGoogle Scholar
  7. Campbell FC, Blarney RW, Woolfson AMJ et al. (1983) Calcium excretion CaE in metastatic breast cancer. Br J Surg 70:202–204PubMedCrossRefGoogle Scholar
  8. Chlebowski RT, Block JB (1981) Chemotherapy of bone metastasis (1). In: Weiss L, Gilbert HA (eds) Bone metastases. GK Hall, Boston, pp 312–324Google Scholar
  9. Chronic Leukaemia-Myeloma Task Force (1973) Proposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Treat Rep 4:145–158Google Scholar
  10. Coleman RE, Rubens RD (1985) Breast cancer and bone metastases. Cancer Treat Rev 12:251–270.PubMedCrossRefGoogle Scholar
  11. Coleman RE, Mashiter G, Fogelman I et al. (1988a) Osteocalcin: a marker of metastatic bone disease. Eur J Cancer Clin Oncol 24:1211–1217PubMedCrossRefGoogle Scholar
  12. Coleman RE, Rubens RD, Fogelman I (1988b) The bone scan flare following systemic therapy for bone metastases. J Nucl Med 29:1354–1359PubMedGoogle Scholar
  13. Coleman RE, Whitaker KD, Moss DW, Mashiter G, Fogelman I, Rubens RD (1988c) Biochemical monitoring predicts response in bone metastases to treatment. Br J Cancer 58:205–210PubMedCrossRefGoogle Scholar
  14. Coleman RE, Woll PJ, Miles M, Scrivener W, Rubens RD (1988d) Treatment of bone metastases from breast cancer with (3-amino-l-hydroxypropylidene)-l, 1-bisphosphonate (APD), Br J Cancer 58:621–625PubMedCrossRefGoogle Scholar
  15. Colomer R, Ruibal A, Salvador L (1989) Circulating tumour marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 64:1674–1681PubMedCrossRefGoogle Scholar
  16. Condon BR, Buchanan R, Garvie NW et al. (1981). Assessment of progression of secondary bone lesions following cancer of the breast or prostate using serial radionuclide imaging. Br J Radiol 54:18–23PubMedCrossRefGoogle Scholar
  17. Coombes RC, Dady P, Parsons C et al. (1983) Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer 52:610–614PubMedCrossRefGoogle Scholar
  18. Crone-Munzebrock RP (1987) Quantification of recalcification of irradiated vertebral body osteolyses by dual-energy computed tomography. Eur J Radiol 7:1–5PubMedGoogle Scholar
  19. Daffner RH, Lupetin RH, Dash N et al. (1986) MRI in the detection of malignant infiltration of the bone marrow. AJR 149:457–469Google Scholar
  20. Dequecker J, Mbuyi-Muamba JM, Holvoet G (1983) Hydroxyproline and bone metastasis. In: Stoll BA, Parbhoo S (eds) Bone metastasis: monitoring and treatment. Raven Press, New York, pp 181–199Google Scholar
  21. Efstradiatis T, Moss DW (1985) Tartrate resistant acid phosphatase of human lung: Apparent identity with osteoclastic acid phosphatase. Enzyme 33:34–40Google Scholar
  22. Frank J, Ling A, Patronas N et al. (1989) Comparison of magnetic resonance imaging and radionuclide bone scan in the evaluation of primary and metastatic disease to bone. Proc ASCO 8:7Google Scholar
  23. Galasko CSB, Bennett A (1976) Mechanism of bone destruction in the development of skeletal metastases. Nature 263:507–508PubMedCrossRefGoogle Scholar
  24. Galen RS, Gambino SR (1975) How to determine the predictive value and efficiency of a test when reading a scientific paper. In: Galen RS, Gambino SR (eds) Beyond normality: the predictive value and efficiency of medical diagnosis. John Wiley & Sons, New York, pp 30–51Google Scholar
  25. Gore ME, Selby PJ, Viner C, Clark PI et al. (1989) Intensive treatment of multiple myeloma and criteria for complete remission. Lancet ii:879– 881Google Scholar
  26. Goris ML, Bretille J (1985) Skeletal scintigraphy for the diagnosis of malignant metastatic disease to the bones. Radiother Oncol 3:319–329PubMedCrossRefGoogle Scholar
  27. Grant CS, Hoare SA, Millis RR, Hayward JL, Wang DY (1984) Urinary hydroxyproline and prognosis in human breast cancer. Br J Surg 71:105–108PubMedCrossRefGoogle Scholar
  28. Gundberg CM, Lian JB, Gallop PM, Steinberg JJ (1984) Urinary gamma-carboxyglutamic acid and serum osteocalcin as bone markers: studies in osteoporosis and Pages disease. J Clin Endocrinol Metab 57:1221–1225CrossRefGoogle Scholar
  29. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD (1977) Assessment of response to therapy in advanced breast cancer. Eur J Cancer Clin Oncol 13:89–94Google Scholar
  30. Hortabagyi GN, Libshitz HI, Seabold JE (1984) Osseous metastases of breast cancer. Clinical, biochemical, radiographic and scintigraphic evaluation of response to therapy. Cancer 55:577–582Google Scholar
  31. Kerin MJ, McAnena OJ, O’Malley VP, Grimes H, Given HF. (1989) CA 15–3: its relationship to clinical stage and progression to metastatic disease in breast cancer. Br J Surg 76:838–839PubMedCrossRefGoogle Scholar
  32. Loprinzi CL, Tormey DC, Rasmussen P et al. (1986) Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer. J Clin Oncol 4:46–56PubMedGoogle Scholar
  33. Mazess A, Vetter J (1985) The influence of marrow on measurement of trabecular bone using computed tomography. Bone 6:349–351PubMedCrossRefGoogle Scholar
  34. Moss DW, Whitby LG (1975) A simplified heat-inactivation method for investigating alkaline phosphatase isoenzymes in serum. Clin Chim Acta 61:63–71PubMedCrossRefGoogle Scholar
  35. Mughal AW, Hortobagyi GN, Fritsche HA, et al. (1983) Serial plasma carcinoembryonic antigen level measurements during treatment of metastatic breast cancer. JAMA 249:1881–1886PubMedCrossRefGoogle Scholar
  36. Mundy A (1979) Urinary hydroxyproline excretion in carcinoma of the prostate: a comparison of 4 different modes of assessment and its role as a marker. Br J Urol 51:570–574PubMedCrossRefGoogle Scholar
  37. Mundy GR (1987) The hypercalcaemia of malignancy. Kidney Int 31:142–155PubMedCrossRefGoogle Scholar
  38. Palazzo S, Liguori V, Molinari B (1986) Is the carcino-embryonic antigen test a valid predictor of response to medical therapy in disseminated breast cancer? Tumori 72:515–518PubMedGoogle Scholar
  39. Parbhoo SP (1983) Serial scintiscans in monitoring patients with bone metastases In: Stoll BA, Parbhoo SP (eds) Bone metastasis: monitoring and treatment. Raven Press, New York, pp 201–239Google Scholar
  40. Parbhoo SP (1985) Usefulness of current techniques in detecting and monitoring bone metastases from breast cancer. J R Soc Med 78:(Suppl 9) 7–10PubMedGoogle Scholar
  41. Peacock M, Robertson WD, Nordin BEC (1969) Relation between serum and urinary calcium with particular reference to parathyroid activities. Lancet i:384– 386Google Scholar
  42. Price PA, Nishimoto SK (1980) Radioimmunoassay for the vitamin K-dependant protein and its discovery in plasma. Proc Natl Acad Sei USA 77:2234–2238CrossRefGoogle Scholar
  43. Rafii M, Firooznia H, Golimbu C, Beranbaum E (1986) CT of skeletal metastasis. Semin Ultrasound, CT MR 7:371–379Google Scholar
  44. Raskin P, McClain C, Medager T (1973) Hypocalcaemia associated with metastatic bone disease. Arch Intern Med 132:539–543PubMedCrossRefGoogle Scholar
  45. Rossleigh MA, Lovegrove FTA, Reynolds PM, Byrne MJ, Whitney BP (1984) The assessment of response to therapy of bone metastases in breast cancer. Aust NZ J Med 14:19–22CrossRefGoogle Scholar
  46. Rubinstein M, Guinan PD, McKiel CF, Dubin A (1988) Review of acid phosphatase in the diagnosis and prognosis of prostatic cancers. Clin Physiol Biochem 6:241–252Google Scholar
  47. Scher HI Yagoda A (1987) Bone metastases: pathogenesis, treatment, and rationale for use of bone resorption inhibitors. A J Med 82:(suppl 2A) 6–28CrossRefGoogle Scholar
  48. Smallridge RC, Wray HL, Schaaf F (1981) Hypocalcaemia with osteoblastic metastases in a patient with prostate carcinoma, A cause of secondary hyperparathyroidism. A J Med 71:184–188CrossRefGoogle Scholar
  49. Smoker WRG, Godersky JC, Knutzon RK, Keyes WD, Norman D, Bergman W (1987) The role of MR imaging in evaluating metastatic spinal disease. A J N R 6:901–908Google Scholar
  50. Stamey TA, Kabalin JN, McNeal JE et al. (1989a) Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 141:1076–1083Google Scholar
  51. Stamey TA, Kabalin JN, Ferrari M, Yang N (1989b) Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol 141:1088–1090PubMedGoogle Scholar
  52. Stepan J, Pacovsky V, Horn V et al. (1978) Relationship of the activity of the bone isoenzyme of serum alkaline phosphatase to urinary hydroxyproline excretion in metabolic and neoplastic bone diseases. Eur J Clin Invest 8:373–377PubMedCrossRefGoogle Scholar
  53. Urwin GH, Percival RC, Yates AJP et al. (1985) Biochemical markers and skeletal metabolism in carcinoma of the prostate. Br J Urol 57:711–714PubMedCrossRefGoogle Scholar
  54. Valentin-Opran A, Charhon SA, Meunier PJ, Edouard CM, Aelot ME (1982) Quantitative histology of myeloma-induced bone changes. Br J Haematol 52:601–610PubMedCrossRefGoogle Scholar
  55. Villalon AH, Tattersall MH, Fox RM, Woods RL (1979) Hypercalcaemia after tamoxifen for breast cancer: a sign of tumour response. Br Med J ii: 1329–1330CrossRefGoogle Scholar
  56. Zweig M, Ihde D (1985) Assessment of serum and enzymatic prostatic acid phosphatase activity in prostate cancer. JAMA 245:1501–1504Google Scholar

Copyright information

© Springer-Verlag London Limited 1991

Authors and Affiliations

  • R. E. Coleman

There are no affiliations available

Personalised recommendations